Southeastern Grocers Inc., the parent company of Winn-Dixie, is selling 8.9 million shares of stock in an initial public offering that will continue to leave a group of investment firms in control.
All of the shares are being sold by the investment firms, with the Jacksonville-based company not receiving any proceeds from the IPO.
An updated registration statement filed with the Securities and Exchange Commission on Jan. 21 shows Fidelity Investments with 21% of Southeastern Grocers’ stock. It will continue to own 20.9% after selling a small number of shares in the IPO.
A company controlled by Lone Star Funds is selling about 4.35 million shares, reducing its stake from 11.6% to 1.5%.
IPO Lockup Expiration Alert: ITeos Therapeutics (ITOS)
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics.
The company s lead drug candidates - EOS-850 and EOS-448 - are in phase 1/2a clinical trials in adult patients with advanced solid tumors and in multiple advanced solid tumors, respectively.
The initial single-agent and combination data from the phase 1/2a clinical trials of EOS-850 are expected in the first half of 2021. The initial safety and efficacy data from phase I/IIa clinical trial of EOS-448 as a monotherapy for patients with solid tumors are also anticipated in the first half of 2021.
iTeos Therapeutics made its debut on The Nasdaq Global Select Market on July 24, 2020, offering its shares at a price of $19 each and as mentioned above, the 180 day lockup period expires on January 20.
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day
News provided by
Share this article
Calliditas Therapeutics AB (publ) ( Calliditas ) (Nasdaq OMX - CALTX) (NASDAQ - CALT)
today announced it will provide information on the near-term clinical development plans for setanaxib in primary biliary cholangitis (PBC) and oncology. It will also present additional data from the Part A of the NefIgArd Phase 3 study, which recently reported positive data.
In Q4 of 2020 Calliditas acquired a controlling stake in Genkyotex, which has been developing a first in class platform for NOX inhibition and where the lead compound, setanaxib has been tested in various fibrosis related indications. Following the positive results from the Phase 1 study in January of 2021, which evaluated higher doses of setanaxib in healthy volunteers, Calliditas is planning to initiate a pivotal Phase 2/3 study in PBC, starting in 2H 20
IPO Lockup Expiration Alert: Inozyme Pharma (INZY)
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Boston, Massachusetts-based Inozyme Pharma (INZY) ends today, i.e., January 20, 2021.
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of calcification disorders of the circulatory system, bones, and kidneys.
The company s lead product candidate, INZ-701, is an enzyme replacement therapy for patients with a variety of calcification disorders linked primarily to Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 or ENPP1 Deficiency and ATP Binding Cassette Subfamily C Member 6 or ABCC6 Deficiency.
Early this month, the company received clearance to initiate a phase I/II clinical trial evaluating INZ-701 in adults with ENPP1 deficiency in the U.S. and United Kingdom. The first subject in the trial is expected to be enrolled in the first half of 2021, with preliminary safety and biomarker data to be provided in the sec
IPO Lockup Expiration Alert: Nurix Therapeutics (NRIX)
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of San Francisco, California-based Nurix Therapeutics (NRIX) expires tomorrow , i.e., January 20, 2021.
Nurix Therapeutics is a biopharmaceutical company developing oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
The company s lead product candidate NX-2127 for the treatment of relapsed or refractory B-cell malignancies, is under pre-clinical testing. Filing of IND for NX-2127 is expected in the first quarter of 2021, with phase I trial to commence thereafter.
Earlier this month, Nurix Therapeutics expanded its global strategic collaboration with Sanofi to develop a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.